We aim to develop new agents and novel approaches across a wide range of cancers, which include targeting tumour vasculature to control tumour growth, invasion and spread.

New approaches

ZD6474 and AZD2171 are anti-angiogenics in phase 2 and phase 1 development respectively which target the control of growth of blood vessels of tumours. AZD9935 is another anti-angiogenic in pre-clinical development.

ZD6126 is a vascular targeting agent designed to target and destroy the vasculature of tumours, working to destroy the tumour from within.

AZD4440 is a vascular targeting agent, a back-up compound to ZD6126.

ZD4054 is an endothelin antagonist in phase 2 development that works by inhibiting the ETA receptor, responsible for tumour cell proliferation.

AZD0530 is an anti-invasive designed to prevent tumours from spreading and is scheduled to enter clinical testing in Q3 2003.

AZD3409 is a prenylation inhibitor designed to inhibit the proliferation of cancer cells and is scheduled to enter clinical testing in Q2 2003.

Broadening the benefit

The potential of Iressa to show benefits in a number of tumours in addition to NSCLC is being investigated with around 60 exploratory trials ongoing. Particular focus is on head and neck cancer, breast cancer and colorectal cancer.